Designated as Outstanding R&D Innovation Product by MSIT (JLK-ICH / JLK UIA)

Designated for Integrated Innovative Medical Device Review (JLK-CTL)

Participated in the APEC Finance Ministers’ Structural Reform Meeting

PMDA approval, Japan (JLK-SWI)

MFDS Class III approval, Korea (JLK-CTP / JLK-PWI)

PMDA approval, Japan (JLK-GRE)

Designated for Integrated Innovative Medical Device Review (JLK-LVO)

FDA clearance, U.S. (Subdural Hemorrhage (SDH) Solution)

PMDA approval, Japan (JLK-FLAIR / JLK-DWI)

PMDA approval, Japan (JLK-NCCT)

FDA clearance, U.S. (Integrated Medical AI Platform JLK-AILink)

FDA clearance, U.S. (JLK-ICH)

Launched FASTRO, the integrated mobile medical app (formerly Snappy)

FDA clearance, U.S. (JLK-PWI)

FDA clearance, U.S. (JLK-LVO / JLK-CTP)

PMDA approval, Japan (JLK-CTP / JLK-PWI)

Designated as Innovative Procurement Product, Korea (JLD-02K(JVIEWER-X))

FDA clearance, U.S. (Medihub Prostate)

First AI Medical Imaging Device in Korea to Receive Non-Reimbursed Coverage (Out-of-Pocket Use) (MOHW Notice No. 2023-255)

Minister’s Award at the AI Convergence Acceleration Project Report

Minister’s Award at the 24th Software Industry Day

Designated as Innovative Medical Device in Korea (First among AI medical devices, Integrated Review, JLK-DWI)

Obtained Malaysian licenses (6 AI medical solutions including 2 stroke solutions)

TFDA approval, Thailand (Cortical atrophy marking solution ATROSCAN)

TFDA approval, Thailand (JLK-DWI)

Designated as Innovative Medical Device in Korea (Standard Review, JLK-DWI)

Innovative medical device company designated by the Ministry of Health and Welfare of Korea

PMDA approval, Japan (JLK-CRP)

Thai approval (JVIEWER-X)

MFDS approval, Korea (JBA-01A)

Selected for national R&D project (AI Cancer analysis solution based on digital pathology, ₩45bil)

Acquired Regulatory Sandbox approval to provide telemedicine services to Koreans living abroad

MFDS approval, Korea (Prostate cancer analysis solution, JPC-01K)

Selected as Data Voucher project supplier company (2-year consecutive) by K-Data

Indonesian approval (JLK-DWI and 3 products)

CE certification, Europe (JVIEWER-X)

Turkish approval (JVIEWER-X and 7 products)

New Zealand approval (diagnostic aid software medical devices)

MFDS approval, Korea (JBS-04A and 3 products)

MFDS approval, Korea (Fundus analysis solution JOD-01A and 2 products)

Australian approval (diagnostic aid software medical devices)

Changed company name to JLK, Inc.

MFDS approval, Korea (Prostate cancer pathology image analysis solution JDP-01A)

CE certification, Europe (Breast cancer detection solution JBD-01K)

MFDS approval, Korea (JVIEWER-X and 2 products)

IPO on KOSDAQ market (1st company to go public in the artificial intelligence medical industry)

Selected as No.1 Lung Abnormalities Diagnosis Solution in Clinton Health Access Initiative (CHAI) International Bidding Project

Received an award by the Minister of Ministry of Science Information and Communication

Vietnamese approval (Cortical atrophy marking solution ATROSCAN)

MFDS approval, Korea (Colon endoscopy analysis solution JFD-01A and 2 products)

MFDS approval, Korea (Chest CT image analysis solution JLD-01K)

CE certification, Europe (Cortical atrophy marking solution ATROSCAN and 4 products)

MFDS approval, Korea (Cortical atrophy marking solution ATROSCAN)

Established a local subsidiary in Tokyo, Japan

Vietnamese approval (JLK-DWI)

Established a local subsidiary in Silicon Valley, USA (JLK Inspection USA)

Commercialization of AI based TB Screening solution at South African Mine (Nominated as the Winner of a Global Competition)

CE certification, Europe (Prostate cancer analysis solution JPC-01K and 2 products)

Investment of 20 billion won by 5 VCs (Series C)

Material Transfer Agreement (MTA) with University of Missouri Hospital for Clinical Trial

Received award by the Minister of Ministry of Health and Welfare

MFDS approval for AI-based brain infarction analysis solution, Korea (First AI-based medical device in Korea)

MFDS approval, Korea (JLK-DWI)

Received citation from the President of the Korea Health Industry Development Institute

Investment of 9.0 billion won by 6 institutions including KHIDI and VCs (Series B, 45x)

Selected as 'K-global 300 Company' by the Ministry of Science and ICT

Acquired Good Manufacturing Practice (GMP) certification for medical device manufacturing and quality management

Selected as 'Top 100 Next Generation Medical Device Company' by KFDA

Investment of 6.5 billion won from 5VCs (Series A, 25x)

Exclusive medical data license agreement with Korean Brain MR Data Center

Established Corporate R&D Center

Investment of 1.5 billion won by technology guarantee fund (Angel Fund, 20x)

Established JLK Inspection Inc.